Total In-Line Products — Total Revenues
Bristol-Myers Squibb Total In-Line Products — Total Revenues decreased by 8.1% to $11.49B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.6%, from $11.20B to $11.49B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration and sustained demand for existing therapies, while a decrease may signal patent expirations, increased generic competition, or market saturation.
Detailed definition
This metric represents the total revenue generated from established, commercially available pharmaceutical products that...
Peer comparison
Peers in the pharmaceutical industry typically report this as 'Established Products' or 'Core Portfolio' revenue, which is essential for assessing the stability of cash flows versus the growth potential of new drug launches.
bmy_segment_in_line_products_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.70B | $11.62B | $7.67B | $11.99B | $11.65B | $8.29B | $11.89B | $8.66B | $11.22B | $8.07B | $11.41B | $8.32B | $11.34B | $8.63B | $11.23B | $8.64B | $10.97B | $8.35B | $11.48B | $8.71B | $11.87B | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B |
| QoQ Change | — | -0.7% | -34.0% | +56.3% | -2.8% | -28.9% | +43.4% | -27.1% | +29.5% | -28.1% | +41.4% | -27.0% | +36.2% | -23.9% | +30.2% | -23.1% | +27.0% | -23.9% | +37.5% | -24.1% | +36.3% | +2.8% | -2.5% | +3.8% | -9.2% | +9.5% | -0.4% | +2.3% | -8.1% |
| YoY Change | — | — | — | — | — | — | +1.6% | -26.0% | -3.5% | -30.6% | -4.8% | -30.6% | -2.7% | -26.0% | -5.6% | -27.3% | -2.2% | -25.6% | +0.6% | -23.7% | +4.7% | +8.7% | +8.4% | +7.5% | -5.6% | +0.6% | +2.8% | +1.3% | +2.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's total in-line products — total revenues?
- Bristol-Myers Squibb (BMY) reported total in-line products — total revenues of $11.49B in Q1 2026.
- How has Bristol-Myers Squibb's total in-line products — total revenues changed year-over-year?
- Bristol-Myers Squibb's total in-line products — total revenues increased by 2.6% year-over-year, from $11.20B to $11.49B.
- What does total in-line products — total revenues mean?
- The total sales revenue generated by the company's established and currently marketed pharmaceutical products.